Literature DB >> 14988643

Hepatitis B virus-associated nephropathy.

Rajendra Bhimma1, Hoosen Mohamed Coovadia.   

Abstract

A direct causal association between hepatitis B virus (HBV) infection and the development of nephropathy remains controversial. Epidemiological studies have shown that chronic carriage of HBV in some individuals (particularly children) leads to the development of nephrotic syndrome with a strong male predominance, the commonest histological type being membranous nephropathy (MN). Spontaneous clearance of HBV antigens (particularly the HBeAg) leads to abrogation of proteinuria. The isolation of immune complexes in the kidney suggests that the pathogenesis of the disease may have an immune-complex basis. Recent studies showing expression of HBV viral antigens in kidney tissue suggest direct viral-induced pathological alterations and chronic immunologic injury. Biosocial studies have detected no correlation between HBV carriage and proteinuria using both quantitative and qualitative urinary protein analysis. Genetic studies of HLA class I and II genes showed a predisposition to MN but no similar correlation in those with milder degrees of proteinuria. These findings suggest that milder proteinuria is unrelated to HBV carriage or genetic factors but the development of nephropathy, particularly MN, in patients with chronic HBV carriage (HBsAg and/or HBV DNA positive) is based on an interaction of virus and host factors. Although the natural history of the disease tends to remission with preservation of renal function, there is considerable morbidity and a small but significant mortality. Use of naturally occurring cytokines (such as interferon-alpha2b) and other candidate therapies accelerates clearance of the virus and proteinuria. The most effective tool in reducing the incidence of the disease is the use of HBV vaccines. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2004        PMID: 14988643     DOI: 10.1159/000077065

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  65 in total

Review 1.  Meta-analysis of combined therapy for adult hepatitis B virus-associated glomerulonephritis.

Authors:  Xiao-Yong Zheng; Ri-Bao Wei; Li Tang; Ping Li; Xiao-Dong Zheng
Journal:  World J Gastroenterol       Date:  2012-02-28       Impact factor: 5.742

2.  Relationship between genotypes and clinical manifestation, pathology, and cccDNA in Chinese children with hepatitis B virus-associated glomerulonephritis.

Authors:  Yong-Hong Sun; Xiao-Yan Lei; Yi-Pa Sai; Jun-Hui Chen; Yuan-Chun Sun; Xia Gao
Journal:  World J Pediatr       Date:  2016-04-08       Impact factor: 2.764

3.  Treatment of hepatitis B virus-associated glomerulonephritis: a meta-analysis.

Authors:  Yu Zhang; Jian-Hua Zhou; Xiao-Ling Yin; Feng-Yu Wang
Journal:  World J Gastroenterol       Date:  2010-02-14       Impact factor: 5.742

4.  A case of anti-GBM glomerulonephritis superimposed on HBV-associated membranous nephropathy.

Authors:  Takeshi Yamamoto; Susumu Oseto; Natsuko Imakita; Masami Inada; Megumu Fukunaga
Journal:  CEN Case Rep       Date:  2013-04-13

Review 5.  Management of patients with hepatitis B in special populations.

Authors:  Evangelos Cholongitas; Konstantinos Tziomalos; Chrysoula Pipili
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

Review 6.  Viral-Associated GN: Hepatitis B and Other Viral Infections.

Authors:  Warren L Kupin
Journal:  Clin J Am Soc Nephrol       Date:  2016-10-18       Impact factor: 8.237

7.  Chronic hepatitis B serum promotes apoptotic damage in human renal tubular cells.

Authors:  Cun-Liang Deng; Xin-Wen Song; Hai-Jun Liang; Chen Feng; Yun-Jian Sheng; Ming-Yong Wang
Journal:  World J Gastroenterol       Date:  2006-03-21       Impact factor: 5.742

8.  Clinicopathological features of cryoglobulinemic glomerulonephritis associated with HBV infection: a retrospective analysis of 8 cases in China.

Authors:  Chen Wang; Zi-Yin Ye; De-Hua Zeng; Fei-Lai Xie; Li-Juan Qu; Zhi-Yong Zheng
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

9.  Combination therapy with lamivudine and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker for hepatitis B virus-associated glomerulonephritis with mild to moderate proteinuria: a clinical review of 38 cases.

Authors:  Li-Jing Sun; Jian-Ping Shan; Ruo-Lan Cui; Wei-Jie Yuan; Geng-Ru Jiang
Journal:  Int Urol Nephrol       Date:  2017-03-10       Impact factor: 2.370

10.  The combination of tacrolimus and entecavir improves the remission of HBV-associated glomerulonephritis without enhancing viral replication.

Authors:  Lifen Wang; Zhiming Ye; Huaban Liang; Bin Zhang; Lixia Xu; Zhonglin Feng; Shuangxin Liu; Wei Shi
Journal:  Am J Transl Res       Date:  2016-03-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.